ImmunityBio
IBRX
263 hedge funds and large institutions have $352M invested in ImmunityBio in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 91 increasing their positions, 58 reducing their positions, and 23 closing their positions.
109% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 23
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
93% more capital inflows, than outflows
Capital inflows: $101M | Capital outflows: $52.4M
57% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 58
9% more funds holding
Funds holding: 242 → 263 (+21)
1.07% more ownership
Funds ownership: 14.07% → 15.14% (+1.1%)
6% less call options, than puts
Call options by funds: $11.7M | Put options by funds: $12.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
+$16.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15M |
| 3 |
Jane Street
New York
|
+$13.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.53M |
| 5 |
BlackRock
New York
|
+$5.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$20.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$18.3M |
| 3 |
Millennium Management
New York
|
-$8.23M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$924K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$888K |
IBRX Hedge Fund Activity: Q3 2025 in Review
263 of the 7,647 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2025, worth a combined $352M — up 7.4% from $328M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new IBRX positions and 23 closed out — a net gain of 25 holders — while 91 added to existing stakes and 58 trimmed.
The largest buyer was Heights Capital Management, opening a new position worth an estimated $16.9M. The largest seller was Armistice Capital, exiting entirely with an estimated $20.5M sold.
- 263 institutional investors held ImmunityBio (IBRX) as of Q3 2025, up from 242 in Q2 2025.
- Funds reported $352M of ImmunityBio stock for Q3 2025, up 7.4% quarter-over-quarter.
- 48 funds opened new ImmunityBio positions in Q3 2025 and 23 closed out, a net change of +25 holders.
- The largest ImmunityBio buyer in Q3 2025 was Heights Capital Management, an estimated $16.9M added.
- The largest ImmunityBio seller in Q3 2025 was Armistice Capital, an estimated $20.5M sold.
Based on aggregated 13F filings for Q3 2025.